Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Discloses CEO Kelly s Severance; Jorge Leon Lands on CytoCore s Medical Advisory Board; Eksigent and Epidauros Tap New CEOs; Myriad s Scholl Moves to Genzyme; and Others

NEW YORK, May 1 (GenomeWeb News) - Orchid Cellmark on April 26 said it had entered into a severance agreement with Paul Kelly, whom Orchid fired March 8. Terms of the agreement call for Orchid to pay Kelly $187,500 in six $31,250 monthly installments.

 

Also that day, Orchid said it has extended the time during which Chairman George Poste will serve as interim CEO. Poste will now man the helm until the company files its quarterly earnings report for the first quarter of 2006 and amends earnings reports for the second and third quarters of 2005. As that time, Thomas Bologna will formally become Orchid's president and CEO.

 

Previously, Orchid said Bolognawould replace Kelly on April 3 or until the company files its 2005 earnings reports.


Epidauros Biotechnology has appointed Michael Lutz as its new CEO, replacing Manfred Zoltobrocki. Lutz joins Epidauros from SuNyx where he most recently worked as CEO and sold its Bioanalytics business to Qiagen. He received his PhD in bio-organic chemistry from the ETH in Z rich, Switzerland.


Jorge Leon has become a member of CytoCore's medical advisory board, and Leon's consultancy, Leomics Associates, will be its consultant.

 

Leonhas a PhD in cellular and molecular biology.


MDS has hired David Spaight as president of MDS Pharma Services, effective immediately. Most recently, Spaight served as senior vice president of global sales and marketing at Fisher Scientific Products. He has a BS in chemistry and an MBA from the Universityof Michigan.


Tom Scholl has been hired by Genzyme Genetics as vice president of technology and development. He comes to Genzyme from Myriad Genetic Laboratories, where he was vice president of technology development.   

 

Scholl has a PhD in molecular and cell biology from Pennsylvania State University, and BSs in microbiology from Long IslandUniversity and the StateUniversityof New York, Plattsburgh.


Eksigent Technologies has hired David Weber as its new CEO and president. Weber, who also becomes a director, joins the company from Stratagene, where he was vice president of global marketing and business.


The Critical Path Institute has appointed Ellen Feigal as its new director of medical devices and imaging. Feigal is on sabbatical from TGen, where she is vice president of clinical sciences and deputy scientific director.

 

Feigal has a BS in biology and an MS in molecular biology and biochemistry from the Universityof California, Irvine, and an MD from UC Davis.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.